Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

S2816

Sigma-Aldrich

SKF-83959 hydrobromide

≥98% (HPLC), solid

Synonym(e):

6-Chloro-7,8-dihydroxy-3-methyl-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

5 MG
CHF 224.00

CHF 224.00

Voraussichtliches Versanddatum29. Mai 2025

Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
5 MG
CHF 224.00

About This Item

Empirische Formel (Hill-System):
C18H20NClO2 · HBr
CAS-Nummer:
80751-85-5
Molekulargewicht:
398.72
MDL-Nummer:
MFCD03792727
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24278699
NACRES:
NA.77

CHF 224.00

Voraussichtliches Versanddatum29. Mai 2025

Bulk-Bestellung anfordern

Assay

≥98% (HPLC)

Form

solid

Farbe

white

Löslichkeit

DMSO: >20 mg/mL
H2O: insoluble

SMILES String

Br[H].CN1CCc2c(Cl)c(O)c(O)cc2C(C1)c3cccc(C)c3

InChI

1S/C18H20ClNO2.BrH/c1-11-4-3-5-12(8-11)15-10-20(2)7-6-13-14(15)9-16(21)18(22)17(13)19;/h3-5,8-9,15,21-22H,6-7,10H2,1-2H3;1H

InChIKey

FHYWNBUFNGHNCP-UHFFFAOYSA-N

Angaben zum Gen

human ... DRD1(1812)

Anwendung

SKF-83959 was used in dopamine signaling studies on eye blinking in monkeys[1] and on phosphorylation of CaMKIIα in mice.[2]

Biochem./physiol. Wirkung

D1 dopamine receptor agonist. Displays antagonist activity in vitro and agonist activity in vivo.
SKF-83959 is an atypical agonist of D1 dopamine receptor and an allosteric modulator of σ-1 receptor on in brain and liver tissues.[3][4] It has neuroprotective and anti-parkinsonian effects through selective activation of phosphoinositol-linked D1 receptor and promotes migration of cultures astrocytes by ERK1/2 activation.[3] In in vitro studies SKF-83959 exhibits antagonist activity against dopamine D1 receptors coupled to adenylyl cyclase.[5]

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000389825
0000389825
0000176744
0000176744
0000134741

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Emily M Jutkiewicz et al.
The Journal of pharmacology and experimental therapeutics, 311(3), 1008-1015 (2004-08-05)
Dopamine D1 ligands have been classified and ordered according to efficacy in both in vitro and in vivo studies. In the present experiments, dopamine D1 ligands reported to differ in in vitro efficacy were evaluated for efficacy-related effects on eye
Hong-Yuan Chu et al.
Brain research, 1343, 20-27 (2010-04-28)
Central dopaminergic system exerts profound modulation on spontaneous glutamate release in various brain regions mainly through D(1) receptor/cAMP/PKA pathway. It remains unclear whether the phosphatidylinositol (PI)-linked D(1)-like receptors are also involved in such modulatory actions. The identification of substituted phenylbenzazepine
Satoshi Fujita et al.
European journal of pharmacology, 632(1-3), 39-44 (2010-02-04)
This study applies new magnetic sensor-electromyographic technology for recording jaw movements in freely moving rats to analyse topographies of orofacial movement that occur in association with individual elements of behaviour under challenge with two dopamine D(1)-like receptor agonists, SKF 83822
A R Cools et al.
Neuropharmacology, 42(2), 237-245 (2002-01-24)
SKF 83959 that has a unique antiparkinson profile in animal models of Parkinson's disease is an in vitro dopamine D1 antagonist of receptors coupled to adenylyl cyclase. We hypothesized that SKF 83959, among others, interacts with dopamine D1 receptors coupled
Ling Zhang et al.
Neurochemistry international, 58(3), 281-294 (2010-12-08)
Accumulating pathological evidence showing layer-specific neuronal reduction, dendrite deficits and brain volume loss have implicated an apoptotic process in schizophrenia, but the exact mechanism remains elusive. Dopamine hyperactivity at D2 receptor sites was considered as an important mechanism in schizophrenia
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.